20 September 2016 – Evolva (SIX: EVE) Evolva announces that its Chief Financial Officer, Jakob Dynnes Hansen, will leave the company for personal reasons. Evolva is in discussion with several suitable external candidates and expects to announce a successor before year-end 2016.
Jakob will stay as CFO until the new candidate is in place, and thereafter support a smooth transition. Jakob will move to a half time role from November 2016, and is currently expected to depart in Q2 2017. Jakob will return to his native Denmark, taking up a part time position at a young pharma-biotech company.
Jakob has been CFO of Evolva for nine years and played a key role in Evolva’s public listing in 2009 and subsequent public financings. He has also been instrumental in building up the company-wide accounting system and governance structure, which are now both firmly in place.
Evolva Chairman Sir Tom McKillop said “I would like to thank Jakob for his important role in helping move Evolva from a privately held, preclinical biotech to where we are today, with multiple products on market and capabilities across the value chain. We are in discussions with several excellent candidates to help take Evolva through the next stage of our development, and in particular to move us over the next few years to being a cash-flow positive company with a sustainable path to significant revenues and EBITDA.”
Jakob Dynnes Hansen said “This was not an easy decision to take. My nine years with Evolva have been very exciting, but also quite demanding. The time has come for me to rebalance and put my experience to work for younger companies. I am proud to have played my part in getting Evolva to where it is today, and confident the Evolva team has all it takes to achieve great success.”
– ends –